Oncotelic (OTLC) CEO boosts stake with 335,759-share open-market buy
Rhea-AI Filing Summary
Oncotelic Therapeutics, Inc. Chairman and CEO Vuong Trieu reported open-market purchases of company common stock. On June 15, 2026, he bought 96,000 shares at $0.05 per share, and on June 17, 2026, he bought 239,759 shares at $0.0446 per share.
After these transactions, his directly held stake is reported as 93,629,319 shares of common stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held through Autotelic Inc., providing a view of both his direct and related-entity ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 335,759 shares
Net Buy
4 txns
Insider
Trieu Vuong
Role
CHAIRMAN AND CEO
Bought
335,759 shs ($15K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 239,759 | $0.0446 | $11K |
| Purchase | Common Stock | 96,000 | $0.045 | $4K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 93,629,319 shares (Direct);
Common Stock — 16,780,384 shares (Indirect, By Autotelic Inc.);
Common Stock — 6,872,529 shares (Indirect, By spouse)
Footnotes (1)
- F1. On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446.
Key Figures
Open-market purchase 1: 96,000 shares at $0.05
Open-market purchase 2: 239,759 shares at $0.0446
Total shares bought: 335,759 shares
+3 more
6 metrics
Open-market purchase 1
96,000 shares at $0.05
Common Stock bought on June 15, 2026
Open-market purchase 2
239,759 shares at $0.0446
Common Stock bought on June 17, 2026
Total shares bought
335,759 shares
Net buy across two open-market transactions
Direct holdings after trades
93,629,319 shares
Common Stock directly owned after June 17, 2026 purchase
Indirect holdings by spouse
6,872,529 shares
Common Stock held indirectly by spouse as of June 15, 2026
Indirect holdings via Autotelic Inc.
16,780,384 shares
Common Stock held indirectly through Autotelic Inc. as of June 15, 2026
Key Terms
open-market purchase, indirect ownership, beneficial ownership, Form 4
4 terms
open-market purchase financial
"purchased 96,000 shares ... from the open market at a price of $0.05"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
"direct_or_indirect: "I", nature_of_ownership: "By spouse""
beneficial ownership financial
"filing lists indirect holdings ... by spouse and by Autotelic Inc."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transactions did Oncotelic (OTLC) report for CEO Vuong Trieu?
Oncotelic reported that CEO Vuong Trieu made two open-market stock purchases, totaling 335,759 common shares. These buys occurred on June 15, 2026 and June 17, 2026, reflecting additional direct investment in the company’s equity.
Were the Oncotelic (OTLC) CEO’s transactions open-market purchases?
Yes. The Form 4 classifies both transactions as open-market purchases of common stock, with transaction code “P” and footnote disclosure stating they were bought from the open market at per-share prices of $0.05 and $0.0446.
AI-generated analysis. How Rhea-AI works. Not financial advice.
